J Rheum Dis 2016; 23(5): 297-303
Published online October 31, 2016
© Korean College of Rheumatology
Correspondence to : Shin-Seok Lee, Division of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea. E-mail:shinseok@chonnam.ac.kr
*These two authors contributed equally to this work.
This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To evaluate the laboratory and clinical manifestations of Sjögren’s syndrome (SS) association with chemokine (C-X-C motif) ligand 1 (CXCL1) expression in the ductal and acinar salivary gland epithelial cells (SGEC) of the minor salivary glands. Methods. The sociodemographic data of 106 SS patients was obtained, and the glandular and extraglandular manifestations of the disease documented. The minor salivary glands were biopsied and the laboratory findings analyzed. European League Against Rheumatism SS disease activity index (ESSDAI) and SS disease damage index (SSDDI) scores were obtained during biopsy. An immunohistochemical approach was used to define the expression of CXCL1 in the salivary glands. Results. Of 106 patients, the minor salivary glands of 22 patients (20.7%) stained positively for CXCL1. Such CXCL1-positive patients exhibited higher ESSDAI scores at the time of biopsy than the CXCL1-negative patients (3.86±2.27 vs. 2.64±1.62, p=0.015). Lymphadenopathy was more frequently observed in CXCL1-positive patients, compared with CXCL1-negative patients (31.8% vs. 9.5%, p=0.014). No differences between groups were identified in terms of sociodemographic characteristics, laboratory data, or the extent of the glandular manifestation of SS. Conclusion. The expression of CXCL1 within the ductal and acinar SGEC of SS patients is associated with lymphadenopathy and elevated clinical disease activity. CXCL1 may play an important role in the disease activity and prognosis of SS.
Keywords Chemokines, CXCL1, Disease activity, Sjögren’s syndrome
J Rheum Dis 2016; 23(5): 297-303
Published online October 31, 2016 https://doi.org/10.4078/jrd.2016.23.5.297
Copyright © Korean College of Rheumatology.
Kyung-Eun Lee1,*, Dong-Jin Park1,*, Sung-Eun Choi1, Ji-Hyoun Kang1, Yi-Rang Yim1, Ji-Eun Kim1, Jeong-Won Lee1, Lihui Wen1, Tae-Jong Kim1, Yong-Wook Park1, Ji Shin Lee2, Kyung Chul Yoon3, Shin-Seok Lee1
1Division of Rheumatology, Department of Internal Medicine, Departments of 2Pathology, 3Ophthalmology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
Correspondence to:Shin-Seok Lee, Division of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea. E-mail:shinseok@chonnam.ac.kr
*These two authors contributed equally to this work.
This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To evaluate the laboratory and clinical manifestations of Sjögren’s syndrome (SS) association with chemokine (C-X-C motif) ligand 1 (CXCL1) expression in the ductal and acinar salivary gland epithelial cells (SGEC) of the minor salivary glands. Methods. The sociodemographic data of 106 SS patients was obtained, and the glandular and extraglandular manifestations of the disease documented. The minor salivary glands were biopsied and the laboratory findings analyzed. European League Against Rheumatism SS disease activity index (ESSDAI) and SS disease damage index (SSDDI) scores were obtained during biopsy. An immunohistochemical approach was used to define the expression of CXCL1 in the salivary glands. Results. Of 106 patients, the minor salivary glands of 22 patients (20.7%) stained positively for CXCL1. Such CXCL1-positive patients exhibited higher ESSDAI scores at the time of biopsy than the CXCL1-negative patients (3.86±2.27 vs. 2.64±1.62, p=0.015). Lymphadenopathy was more frequently observed in CXCL1-positive patients, compared with CXCL1-negative patients (31.8% vs. 9.5%, p=0.014). No differences between groups were identified in terms of sociodemographic characteristics, laboratory data, or the extent of the glandular manifestation of SS. Conclusion. The expression of CXCL1 within the ductal and acinar SGEC of SS patients is associated with lymphadenopathy and elevated clinical disease activity. CXCL1 may play an important role in the disease activity and prognosis of SS.
Keywords: Chemokines, CXCL1, Disease activity, Sjö,gren’s syndrome
Ki-Jeong Park, Hye-Mi Jin, Young-Nan Cho, Jeong-Hwa Kang, Hyun-Ju Jung, Ji-Hyoun Kang, Ji-Eun Kim,
Yi-Rang Yim, Jeong-Won Lee, Kyung-Eun Lee, Dong-Jin Park, Tae-Jong Kim, Shin-Seok Lee, Seung-Jung Kee,
Yong-Wook Park
Hye-Jin Jeong, Tae Han Lee, Ji Min Lee, Go Choi, Chang-Nam Son, Ji-Min Kim, Yong Won Cho, Sang-Hyon Kim
J Rheum Dis 2014; 21(5): 241-247Dae Chul Jeong
J Rheum Dis 2014; 21(6): 289-296